ClinicalTrials.gg
CompletedNCT03639623Updated Oct 24, 2024Results posted

Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)

A Phase 2 interventional study of Saroglitazar in Liver Transplant; Complications and NAFLD, sponsored by Zydus Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
365th of 460
20 · median 56
Started
2019
with 61 others
Phase 2
192 of 547
15 open now
Registered
252nd of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 365th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 252nd registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2A, single center, open-label, single-arm, 24-week study to evaluate the safety, tolerability and efficacy of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD.

Read the detailed description

This is a phase 2A, single center, open-label, single-arm, 24-week study to evaluate the safety, tolerability and efficacy of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD.

The study will be conducted over a period of up to 33 weeks and will include 5 weeks screening, a 24 week treatment period and 4 week follow-up period. The primary end point of the study is to assess the safety of Saroglitazar Magnesium 4 mg in liver transplant recipients with NAFLD over 24 weeks of treatment.

03

Conditions studied

  • Liver Transplant; Complications
  • NAFLD

Keywords

  • Peroxisome proliferator-activated receptors
  • NAFLD
  • NASH
  • Post Transplant Metabolic Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to give written .
  • Males or females, 18 to 75 years of age.
  • Patients who are at least 6 months post-transplant for nonalcoholic steatohepatitis (NASH) or cryptogenic cirrhosis thought to be secondary to NASH are eligible for enrolment.
  • The presence of NAFLD determined by Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) prior to enrollment.
  • Patients with ≤20% variance in the levels of (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total between Visit 1 and Visit 1.1.
  • History of medical compliance with .
  • Female subjects of non-child bearing potential or on highly effective . For male subjects with female partners of , willing to follow highly effective contraception measures during the study, either by the male participant or his female partner or both.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females.
  • Patient with abnormal transaminases due to secondary intercurrent illness.
  • Patients with bile duct strictures.
  • Other causes of chronic liver disease after liver transplantation including , viral, and alcoholic liver disease.
  • Graft cirrhosis as defined by:

    1. Cirrhosis on historical liver .
    2. Evidence of cirrhosis on imaging including portal venous collaterals.
    3. Prior history of decompensated liver disease including ascites, hepatic encephalopathy or variceal bleeding.
    4. Evidence of esophageal varices on prior endoscopy.
  • (BMI) \<18 kg/m².
  • Subjects with change in body weight >5% in the 3 months prior to enrollment.
  • Subjects requiring or anticoagulation therapy.
  • History of myopathies or evidence of active muscle diseases.
  • Unstable cardiovascular disease.
  • History of bladder disease and/or hematuria or has current hematuria unless due to a urinary tract infection.
  • Active post-liver transplantation.
  • History of malignancy in the past 5 years and/or active neoplasm.
  • History of chronic rejection of liver transplant graft.
  • Acute cellular rejection of liver transplant graft within the past 6 months.
  • Evidence of Acute cellular rejection (ACR) or chronic rejection (CR) or alternative etiologies to NAFLD.
  • Poorly controlled diabetes as defined by an >8.5% within the past 6 months.
  • History of excessive alcohol intake.
  • Subject tests positive for a urine drug screen.
  • Subject has a history of chronic (uncontrolled) pain.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Saroglitazar Magnesium 4 mg

    Saroglitazar Magnesium tablet once daily in the morning 60 minutes before breakfast

    Drug: Saroglitazar

Interventions

  • Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food

    Also known as: Not any

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events Assessed by CTCAE

    Safety measured by adverse events, vital signs, physical exams, body weight, electrocardiograms (ECGs) and lab results (including hematology, chemistry and urinalysis)

    Time frame: 24 weeks

Secondary outcomes

  1. Hepatic Fat

    Changes in hepatic fat as determined by MRI-PDFF from baseline to end-of-treatment (EOT)

    Time frame: Baseline and week 24

  2. Liver Stiffness

    Changes in Liver stiffness as determined by MRE from baseline to end-of-treatment (EOT) Liver stiffness is a measure of a mechanical property of tissue (stiffness). This can be measured non-invasively by MR elastography, a technique that involves applying an external vibration to the abdomen and measuring the progression of shear waves through the underlying liver using MRI.

    Time frame: Baseline and Week 24

  3. Frequently Sampled Intravenous Glucose Tolerance Test (Insulin Resistance Marker)

    Changes in frequently sampled intravenous glucose tolerance test (FSIVGTT) from baseline to EOT

    Time frame: Baseline and Week 24

  4. Glycosylated Hemoglobin (Insulin Resistance Marker)

    Changes in glycosylated hemoglobin (HbA1c) from baseline to EOT

    Time frame: Baseline and Week 24

  5. Fructosamine (Insulin Resistance Marker)

    Changes in fructosamine from baseline to EOT

    Time frame: Baseline and Week 24

  6. Serum Liver Enzymes

    Changes in serum liver enzymes from baseline to EOT

    Time frame: Baseline and Week 24

  7. Serum Liver Enzymes; Bilirubin

    Changes in bilirubin from baseline to EOT

    Time frame: Baseline and Week 24

  8. Serum Lipids

    Changes in serum lipids from baseline to EOT

    Time frame: Baseline and Week 24

  9. Small Dense Low-density Lipoprotein (Atherogenic Lipoprotein)

    Changes in small dense low-density lipoprotein (sdLDL) from baseline to EOT

    Time frame: Baseline and Week 24

  10. LDL Size (Atherogenic Lipoprotein)

    Changes in LDL size from baseline to EOT

    Time frame: Baseline and Week 24

  11. LDL Concentration (Atherogenic Lipoprotein)

    Changes in LDL concentration from baseline to EOT

    Time frame: Baseline and Week 24

  12. Very Low-density Lipoprotein (Atherogenic Lipoprotein)

    Changes in subtypes of very low-density lipoprotein (VLDL) from baseline to EOT

    Time frame: Baseline and Week 24

  13. Very Low-density Lipoprotein Chylomicron Triglyceride (Atherogenic Lipoprotein)

    Changes in VLDL chylomicron triglyceride from baseline to EOT

    Time frame: Baseline and Week 24

  14. High-density Lipoprotein (Atherogenic Lipoprotein)

    Changes in high-density lipoprotein (HDL) from baseline to EOT

    Time frame: Baseline and Week 24

  15. Change in Metabolic Flexibility; Time to Peak RQ

    Metabolic flexibility was measured via a whole room calorimeter (i.e. respiration chamber). The CO2 production and O2 consumption were recorded every minute for a total of 18 hours while study participants were in the respiration chamber on baseline and Week 24. Metabolic flexibility was quantified by measuring whole-body CO2 production relative to O2 consumption or respiratory quotient (RQ). The RQ oscillates between 0.7 and 1.0, which is indicative of either predominantly fatty acid or carbohydrate oxidation, respectively. The time to maximal carbohydrate consumption is measured by the time it takes to reach peak RQ after a standardized meal, whereas maximal carbohydrate consumption is measured at the peak of RQ vs. time curve. Next, the transition from maximal carbohydrate consumption to maximal fatty acid consumption is measured from peak RQ to lowest RQ. Finally, fasting biofuel utilization is measured in the fasting state and represents predominantly fatty acid oxidation.

    Time frame: Baseline and Week 24

  16. Quality of Life (SF-36 Health Survey)

    Change in Quality of life score from baseline to EOT The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as the worst health status

    Time frame: Baseline and Week 24

  17. Peak Plasma Concentration [Cmax]

    Pharmacokinetics of Saroglitazar following first and last dose.

    Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose

  18. Time to Reach Peak Plasma Concentration [Tmax]

    Pharmacokinetics of Saroglitazar following first and last dose

    Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose

  19. Area Under Plasma Concentration vs. Time Curve Till the Last Time Point [AUC0-t]

    Pharmacokinetics of Saroglitazar

    Time frame: PK Sampling time points: Day 1 visit at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose

  20. Area Under Plasma Concentration vs. Time Curve Extrapolated to the Infinity [AUC0-∞]

    Pharmacokinetics of Saroglitazar

    Time frame: PK Sampling time points: Day 1 visit at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose

  21. Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval [AUCtau]

    Pharmacokinetics of Saroglitazar

    Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose

  22. Elimination Rate Constant [λz]

    Pharmacokinetics of Saroglitazar

    Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose

  23. Elimination Half-life [t1/2]

    Pharmacokinetics of Saroglitazar

    Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose

  24. Apparent Volume of Distribution [Vd/F]

    Pharmacokinetics of Saroglitazar

    Time frame: PK Sampling time points: Day 1 (Baseline) and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose

  25. Apparent Clearance [CL/F]

    Pharmacokinetics of Saroglitazar

    Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose

  26. Minimal or Trough Plasma Concentration [Cmin]

    Pharmacokinetics of Saroglitazar

    Time frame: PK Sampling time points: Week 24 visit at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose

  27. Accumulation Index Calculated as a Ratio of AUCtau (Last Dose)/AUCtau (First Dose)

    Pharmacokinetics of Saroglitazar

    Time frame: PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose

  28. Fluctuation Index

    Fluctuation index is the peak trough fluctuation within complete dosing interval at steady state, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100

    Time frame: PK Sampling time points: Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose

07

Results

Posted Oct 24, 2024

Participant flow

Participant flow — Overall Study
MilestoneSaroglitazar Magnesium 4 mg
Started20
Completed15
Not completed5

Outcome measures

PrimaryNumber of Participants With Adverse Events Assessed by CTCAE

Safety measured by adverse events, vital signs, physical exams, body weight, electrocardiograms (ECGs) and lab results (including hematology, chemistry and urinalysis)

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Assessed by CTCAE
ParticipantsSaroglitazar Magnesium 4 mg
Number of Participants With Adverse Events Assessed by CTCAE12
SecondaryHepatic Fat

Changes in hepatic fat as determined by MRI-PDFF from baseline to end-of-treatment (EOT)

Time frame:
Baseline and week 24
Reported as:
Mean · percentage of hepatic fat
Hepatic Fat
percentage of hepatic fatSaroglitazar Magnesium 4 mg
Hepatic Fat-3.17 ± 5.82
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.053
SecondaryLiver Stiffness

Changes in Liver stiffness as determined by MRE from baseline to end-of-treatment (EOT) Liver stiffness is a measure of a mechanical property of tissue (stiffness). This can be measured non-invasively by MR elastography, a technique that involves applying an external vibration to the abdomen and measuring the progression of shear waves through the underlying liver using MRI.

Time frame:
Baseline and Week 24
Reported as:
Mean · kPa
Liver Stiffness
kPaSaroglitazar Magnesium 4 mg
Liver Stiffness0.01 ± 0.34
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.958
SecondaryFrequently Sampled Intravenous Glucose Tolerance Test (Insulin Resistance Marker)

Changes in frequently sampled intravenous glucose tolerance test (FSIVGTT) from baseline to EOT

Time frame:
Baseline and Week 24
Reported as:
Mean · mg/dL
Frequently Sampled Intravenous Glucose Tolerance Test (Insulin Resistance Marker)
mg/dLSaroglitazar Magnesium 4 mg
Frequently Sampled Intravenous Glucose Tolerance Test (Insulin Resistance Marker)-22.68 ± 29.99
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.011
SecondaryGlycosylated Hemoglobin (Insulin Resistance Marker)

Changes in glycosylated hemoglobin (HbA1c) from baseline to EOT

Time frame:
Baseline and Week 24
Reported as:
Mean · percentage of glycosylated hemoglobin
Glycosylated Hemoglobin (Insulin Resistance Marker)
percentage of glycosylated hemoglobinSaroglitazar Magnesium 4 mg
Glycosylated Hemoglobin (Insulin Resistance Marker)-0.11 ± 0.57
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.454
SecondaryFructosamine (Insulin Resistance Marker)

Changes in fructosamine from baseline to EOT

Time frame:
Baseline and Week 24
Reported as:
Mean · µmol/L
Fructosamine (Insulin Resistance Marker)
µmol/LSaroglitazar Magnesium 4 mg
Fructosamine (Insulin Resistance Marker)-10.90 ± 28.13
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.154
SecondarySerum Liver Enzymes

Changes in serum liver enzymes from baseline to EOT

Time frame:
Baseline and Week 24
Reported as:
Mean · U/L
Serum Liver Enzymes
U/LSaroglitazar Magnesium 4 mg
Change in ALT-9.10 ± 23.23
Change in AST3.90 ± 17.56
Change in ALP-42.80 ± 22.07
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.125
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.375
  • Saroglitazar Magnesium 4 mg · paired t-test · p = <0.001
SecondarySerum Liver Enzymes; Bilirubin

Changes in bilirubin from baseline to EOT

Time frame:
Baseline and Week 24
Reported as:
Mean · mg/dL
Serum Liver Enzymes; Bilirubin
mg/dLSaroglitazar Magnesium 4 mg
Serum Liver Enzymes; Bilirubin-0.08 ± 0.16
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.054
SecondarySerum Lipids

Changes in serum lipids from baseline to EOT

Time frame:
Baseline and Week 24
Reported as:
Mean · mg/dL
Serum Lipids
mg/dLSaroglitazar Magnesium 4 mg
Change in Total Cholesterol-5.50 ± 20.74
Change in Triglycerides-43.20 ± 47.92
Change in Non-HDL-C-6.20 ± 17.31
Change in HDL-C0.20 ± 10.27
Change in HDL-C Subclass 2-5.30 ± 9.39
Change in HDL-C Subclass 35.10 ± 5.75
Change in LDL-C2.90 ± 19.40
Change in VLDL-C-8.50 ± 9.49
Change in VLDL concentration-6.60 ± 13.63
Change in Small dense LDL-C-4.29 ± 5.17
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.378
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.010
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.264
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.954
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.127
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.029
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.630
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.010
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.160
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.020
SecondarySmall Dense Low-density Lipoprotein (Atherogenic Lipoprotein)

Changes in small dense low-density lipoprotein (sdLDL) from baseline to EOT

Time frame:
Baseline and Week 24
Reported as:
Mean · nmol/L
Small Dense Low-density Lipoprotein (Atherogenic Lipoprotein)
nmol/LSaroglitazar Magnesium 4 mg
Small Dense Low-density Lipoprotein (Atherogenic Lipoprotein)51.40 ± 248.45
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.529
SecondaryLDL Size (Atherogenic Lipoprotein)

Changes in LDL size from baseline to EOT

Time frame:
Baseline and Week 24
Reported as:
Mean · nm
LDL Size (Atherogenic Lipoprotein)
nmSaroglitazar Magnesium 4 mg
LDL Size (Atherogenic Lipoprotein)0.17 ± 0.61
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.403
SecondaryLDL Concentration (Atherogenic Lipoprotein)

Changes in LDL concentration from baseline to EOT

Time frame:
Baseline and Week 24
Reported as:
Mean · nmol/L
LDL Concentration (Atherogenic Lipoprotein)
nmol/LSaroglitazar Magnesium 4 mg
LDL Concentration (Atherogenic Lipoprotein)21.70 ± 155.44
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.669
SecondaryVery Low-density Lipoprotein (Atherogenic Lipoprotein)

Changes in subtypes of very low-density lipoprotein (VLDL) from baseline to EOT

Time frame:
Baseline and Week 24
Reported as:
Mean · nmol/L
Very Low-density Lipoprotein (Atherogenic Lipoprotein)
nmol/LSaroglitazar Magnesium 4 mg
Change in VLDL chylomicron particles-20.22 ± 22.92
Change in Large VLDL chylomicron particles-2.20 ± 2.19
Change in Medium VLDL particles-13.24 ± 19.47
Change in Small VLDL particles-4.79 ± 14.53
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.021
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.011
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.060
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.324
SecondaryVery Low-density Lipoprotein Chylomicron Triglyceride (Atherogenic Lipoprotein)

Changes in VLDL chylomicron triglyceride from baseline to EOT

Time frame:
Baseline and Week 24
Reported as:
Mean · mg/dL
Very Low-density Lipoprotein Chylomicron Triglyceride (Atherogenic Lipoprotein)
mg/dLSaroglitazar Magnesium 4 mg
Very Low-density Lipoprotein Chylomicron Triglyceride (Atherogenic Lipoprotein)-40.70 ± 39.77
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.010
SecondaryHigh-density Lipoprotein (Atherogenic Lipoprotein)

Changes in high-density lipoprotein (HDL) from baseline to EOT

Time frame:
Baseline and Week 24
Reported as:
Mean · µmol/L
High-density Lipoprotein (Atherogenic Lipoprotein)
µmol/LSaroglitazar Magnesium 4 mg
High-density Lipoprotein (Atherogenic Lipoprotein)1.82 ± 4.67
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.249
SecondaryChange in Metabolic Flexibility; Time to Peak RQ

Metabolic flexibility was measured via a whole room calorimeter (i.e. respiration chamber). The CO2 production and O2 consumption were recorded every minute for a total of 18 hours while study participants were in the respiration chamber on baseline and Week 24. Metabolic flexibility was quantified by measuring whole-body CO2 production relative to O2 consumption or respiratory quotient (RQ). The RQ oscillates between 0.7 and 1.0, which is indicative of either predominantly fatty acid or carbohydrate oxidation, respectively. The time to maximal carbohydrate consumption is measured by the time it takes to reach peak RQ after a standardized meal, whereas maximal carbohydrate consumption is measured at the peak of RQ vs. time curve. Next, the transition from maximal carbohydrate consumption to maximal fatty acid consumption is measured from peak RQ to lowest RQ. Finally, fasting biofuel utilization is measured in the fasting state and represents predominantly fatty acid oxidation.

Time frame:
Baseline and Week 24
Reported as:
Mean · minutes
Change in Metabolic Flexibility; Time to Peak RQ
minutesSaroglitazar Magnesium 4 mg
Change in Metabolic Flexibility; Time to Peak RQ-53.2 ± 78.0
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.0193
SecondaryQuality of Life (SF-36 Health Survey)

Change in Quality of life score from baseline to EOT The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as the worst health status

Time frame:
Baseline and Week 24
Reported as:
Mean · score on a scale
Quality of Life (SF-36 Health Survey)
score on a scaleSaroglitazar Magnesium 4 mg
Physical Component Score-0.10 ± 7.54
Mental Component Score2.63 ± 8.45
Statistical analysis
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.960
  • Saroglitazar Magnesium 4 mg · paired t-test · p = 0.249
SecondaryPeak Plasma Concentration [Cmax]

Pharmacokinetics of Saroglitazar following first and last dose.

Time frame:
PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Reported as:
Mean · ng/mL
Peak Plasma Concentration [Cmax]
ng/mLSaroglitazar Magnesium 4 mg
first dose (Day 1)174.783 ± 53.673
last dose (Week 24)115.687 ± 62.680
SecondaryTime to Reach Peak Plasma Concentration [Tmax]

Pharmacokinetics of Saroglitazar following first and last dose

Time frame:
PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Reported as:
Median · hours
Time to Reach Peak Plasma Concentration [Tmax]
hoursSaroglitazar Magnesium 4 mg
First dose (Day 1)1.010 (1.000 to 3.000)
Last dose (Week 24)2.500 (0.500 to 4.000)
SecondaryArea Under Plasma Concentration vs. Time Curve Till the Last Time Point [AUC0-t]

Pharmacokinetics of Saroglitazar

Time frame:
PK Sampling time points: Day 1 visit at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Reported as:
Mean · (ng/mL)*(hr)
Area Under Plasma Concentration vs. Time Curve Till the Last Time Point [AUC0-t]
(ng/mL)*(hr)Saroglitazar Magnesium 4 mg
Area Under Plasma Concentration vs. Time Curve Till the Last Time Point [AUC0-t]689.550 ± 380.816
SecondaryArea Under Plasma Concentration vs. Time Curve Extrapolated to the Infinity [AUC0-∞]

Pharmacokinetics of Saroglitazar

Time frame:
PK Sampling time points: Day 1 visit at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Reported as:
Mean · (ng/mL)*(hr)
Area Under Plasma Concentration vs. Time Curve Extrapolated to the Infinity [AUC0-∞]
(ng/mL)*(hr)Saroglitazar Magnesium 4 mg
Area Under Plasma Concentration vs. Time Curve Extrapolated to the Infinity [AUC0-∞]698.354 ± 386.372
SecondaryArea Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval [AUCtau]

Pharmacokinetics of Saroglitazar

Time frame:
PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Reported as:
Mean · (ng/mL)*(hr)
Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval [AUCtau]
(ng/mL)*(hr)Saroglitazar Magnesium 4 mg
First dose (Day 1)689.504 ± 380.751
Last dose (Week 24)805.178 ± 513.106
SecondaryElimination Rate Constant [λz]

Pharmacokinetics of Saroglitazar

Time frame:
PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Reported as:
Mean · L/hour
Elimination Rate Constant [λz]
L/hourSaroglitazar Magnesium 4 mg
First dose (Day 1)0.167 ± 0.020
last dose (Week 24)0.159 ± 0.024
SecondaryElimination Half-life [t1/2]

Pharmacokinetics of Saroglitazar

Time frame:
PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Reported as:
Mean · hour
Elimination Half-life [t1/2]
hourSaroglitazar Magnesium 4 mg
First dose (Day 1)4.199 ± 0.479
Last dose (Week 24)4.442 ± 0.612
SecondaryApparent Volume of Distribution [Vd/F]

Pharmacokinetics of Saroglitazar

Time frame:
PK Sampling time points: Day 1 (Baseline) and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Reported as:
Mean · mL
Apparent Volume of Distribution [Vd/F]
mLSaroglitazar Magnesium 4 mg
First dose44028.830 ± 21667.338
Last dose40693.327 ± 18934.484
SecondaryApparent Clearance [CL/F]

Pharmacokinetics of Saroglitazar

Time frame:
PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Reported as:
Mean · (mL/hr)
Apparent Clearance [CL/F]
(mL/hr)Saroglitazar Magnesium 4 mg
First dose (Day 1)7064.331 ± 3062.337
Last dose (Week 24)6658.927 ± 3972.114
SecondaryMinimal or Trough Plasma Concentration [Cmin]

Pharmacokinetics of Saroglitazar

Time frame:
PK Sampling time points: Week 24 visit at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Reported as:
Mean · ng/mL
Minimal or Trough Plasma Concentration [Cmin]
ng/mLSaroglitazar Magnesium 4 mg
Minimal or Trough Plasma Concentration [Cmin]2.321 ± 1.994
SecondaryAccumulation Index Calculated as a Ratio of AUCtau (Last Dose)/AUCtau (First Dose)

Pharmacokinetics of Saroglitazar

Time frame:
PK Sampling time points: Day 1 and Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Reported as:
Mean · ratio
Accumulation Index Calculated as a Ratio of AUCtau (Last Dose)/AUCtau (First Dose)
ratioSaroglitazar Magnesium 4 mg
Accumulation Index Calculated as a Ratio of AUCtau (Last Dose)/AUCtau (First Dose)1.134 ± 0.203
SecondaryFluctuation Index

Fluctuation index is the peak trough fluctuation within complete dosing interval at steady state, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100

Time frame:
PK Sampling time points: Week 24 visits at pre-dose (0), 0.5, 1.0, 2, 3, 4, 6, 8, 10 and 24-hour post-dose
Reported as:
Mean · percentage
Fluctuation Index
percentageSaroglitazar Magnesium 4 mg
Fluctuation Index374.965 ± 182.252

Adverse events

Collected over 28 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saroglitazar Magnesium 4 mg0/20 (0%)2/20 (10%)12/20 (60%)
Most frequent serious events
Most frequent serious events
EventSaroglitazar Magnesium 4 mg
Mesenteric vein thrombosisGastrointestinal disorders1/20
Gastroenteritis viralInfections and infestations1/20
Most frequent other events
Showing 10 of 27
Most frequent other events
EventSaroglitazar Magnesium 4 mg
Glomerular filtration rate decreasedInvestigations3/20
Alanine aminotransferase increasedInvestigations2/20
Aspartate aminotransferase increasedInvestigations2/20
Blood creatinine increasedInvestigations2/20
Lipase increasedInvestigations2/20
Abdominal painGastrointestinal disorders2/20
DiarrhoeaGastrointestinal disorders2/20
CellulitisInfections and infestations2/20
HypoglycaemiaMetabolism and nutrition disorders2/20
Anal incontinenceGastrointestinal disorders1/20

Baseline characteristics

Safety Population

Age, Continuous
Age, Continuous(years)Saroglitazar Magnesium 4 mg
Mean58.7 ± 10.96
Sex: Female, Male
Sex: Female, Male(Participants)Saroglitazar Magnesium 4 mg
Female2
Male18
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Saroglitazar Magnesium 4 mg
Hispanic or Latino1
Not Hispanic or Latino19
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Saroglitazar Magnesium 4 mg
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White16
More than one race0
Unknown or Not Reported0
Body Mass Index
Body Mass Index(kg/m2)Saroglitazar Magnesium 4 mg
Mean36.8 ± 6.77
08

Study locations

1 site
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
09

References and documents

Publications

  • Bhati C, Idowu MO, Sanyal AJ, Rivera M, Driscoll C, Stravitz RT, Kohli DR, Matherly S, Puri P, Gilles H, Cotterell A, Levy M, Sterling RK, Luketic VA, Lee H, Sharma A, Siddiqui MS. Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis. Transplantation. 2017 Aug;101(8):1867-1874. doi: 10.1097/TP.0000000000001709. PubMed 28296807 ↗
  • Siddiqui MS, Parmar D, Shaikh F, Forsgren M, Patel S, Bui AT, Boyett S, Patel V, Sanyal AJ. Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients. Liver Transpl. 2023 Sep 1;29(9):979-986. doi: 10.1097/LVT.0000000000000110. Epub 2023 Feb 28. PubMed 36847136 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Dec 2021, 33 months.

Results were first posted in Oct 2024, 2 years 10 months after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 33 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2018
First posted
Aug 21, 2018
StartActual
Feb 25, 2019
Primary completionActual
Dec 13, 2021
CompletionActual
Dec 13, 2021
Results first posted
Oct 24, 2024
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03639623
Responsible party
Sponsor
First posted
Aug 21, 2018
Start date
Feb 25, 2019
Primary completion
Dec 13, 2021
Completion
Dec 13, 2021
Results posted
Oct 24, 2024
Last update
Oct 24, 2024

Study contacts

Deven Parmar, MD FCP
study director · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saroglitazar

Start the discussion